fenoldopam (Rx)

  • Print
Brand and Other Names:Corlopam

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 10mg/mL
more...

Severe/Malignant Hypertension, Hypertensive Emergencies

Initiate dosing at 0.01 to 0.3 mcg/kg/min by continuous IV infusion 

Titrate by 0.05-0.1 mcg/kg/min q15min or longer until target blood pressure reached; up to 1.6 mcg/kg/min used in clinical trials; may continue maintenance infusion for up to 48 hr

In hospital use only

Monitor

Continuously monitor BP (usually by means of an intra-arterial line) & heart rate

Other Indications & Uses

Short-term (No more than 48 hr adult, 4 hr Peds), in-hospital treatment of

  • Severe or malignant hypertension
  • Hypertensive emergencies

Dosage Forms & Strengths

injectable solution

  • 10mg/mL
more...

Severe/Malignant HTN, Hypertensive Emergencies

Initial 0.2 mcg/kg/min continuous IV infusion pump for <4 hr 

Titrate q20-30min up to 0.3-0.5 mcg/kg/min; not to exceed 0.8 mcg/kg/min

In hospital use only

Monitor

Continuously monitor BP (usually by means of an intra-arterial line) & heart rate

Next:

Interactions

Interaction Checker

and fenoldopam

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Angina

            Cardiac dysrhythmia

            Dizziness

            Flushing

            Heart failure

            Hypotension

            Myocardial infarction

            Tachycardia

            Headache

            Nausea

            Vomiting

            Serum creatinine raised

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity to fenoldopam and sulfite

            Cautions

            Causes a dose-related tachycardia, particularly with infusion rates above 0.1 mcg/kg/min

            Monitor potassium levels

            Increased intraocular pressure in patients with glaucoma or intraocular hypertension

            Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms in susceptible patients

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: B

            Lactation: Excretion in milk unknown; use with caution

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next:

            Pharmacology

            Mechanism of Action

            D1-dopamine receptor agonist: rapid-acting vasodilator; decreases peripheral resistance and increases renal blood flow; has minimal adrenergic effects

            Also diuretic, natriuretic

            Pharmacokinetics

            Half-Life: 5 min

            Duration: 1-4 hr post infusion

            Onset: initial effect: 10 min, max effect: 30-120 min

            Vd: 0.6 L/kg

            Metabolism: in the liver to a variety of sulfate, glucuronide, & methoxy metabolites

            Metabolite: fenoldopam-8-sulfate, fenoldopam-7-sulfate, fenoldopam glucuronide conjugates, and other minor metabolites

            Excretion: Urine (90%), feces (10%)

            Previous
            Next:

            Administration

            IV Incompatibilities

            Y-site: aminophylline, amphotericin B, ampicillin, bumetanide, cefoxitin, dexamethasone sodium PO4, diazepam, fosphenytoin, furosemide, ketorolac, methohexital, methylprednisolone Na-succinate, pentobarbital, phenytoin, prochlorperazine, Na-bicarb, thiopental

            IV Compatibilities

            Solution: D5W, NS

            Y-site (partial list): alfentanil, atropine, cefazolin, cefepime, ciprofloxacin, cisatracurium, clindamycin, dalfopristin-quinupristin, digoxin, diltiazem, dobutamine, dopamine, epinephrine, erythromycin, esmolol, heparin, hydromorphone, hydroxyzine, linezolid, lorazepam, MgSO4, morphine SO4, mannitol, midazolam, nitroglycerin, KCl, propofol, propranolol, TMP-SMX, vancomycin, verapamil

            IV Preparation

            Adult Infusion: dilute in NS or D5W to a final concentration of 40 mcg/mL; for each 1 mL (=10 mg) of drug use 250 mL diluent

            Pediatric Infusion: dilute in NS or D5W to a final concentration of 60 mcg/mL; for each 1.5 mL (=15 mg) of drug use 250 mL diluent

            IV Administration

            Use diluted solution within 24 hr

            Use continuous infusion pump

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous